Asthma - Epidemiology Forecast to 2029

Summary

Asthma is a common respiratory condition that affects the lungs. The airways in the lungs narrow and well, causing obstruction to the airflow (CDC, 2013; NHS, 2018). For some people asthma is mild, but in severe cases, people can experience life-threatening asthma attacks (Mayo Clinic, 2018). In most cases, the cause of asthma is unknown, and although there is no cure, medication can help control asthma (CDC, 2013). Asthma can develop at any stage of life. Often, in children, asthma can resolve during their teenage years; however, it is usually a long-term illness, especially if it first develops in adulthood (NHS, 2018).

The publisher's epidemiologists used age- and sex-specific lifetime diagnosed prevalence rates to forecast the lifetime diagnosed prevalent cases. The publisher's epidemiologists applied country-specific lifetime diagnosed prevalence rates of asthma, wherever available, to each country’s population to obtain the number of estimated lifetime diagnosed prevalent cases. Lifetime diagnosed prevalent cases were also segmented by severity of asthma.

The following data describes epidemiology of asthma cases. In 2019, the 7MM had 86,751,036 lifetime diagnosed prevalent cases of asthma. This is expected to increase to 89,414,720 cases by 2029, at an Annual Growth Rate (AGR) of 0.31%. The increase is driven by changes in the in the underlying population structure such as aging and population growth in the 7MM. In 2019, intermittent asthma was the most predominant severity in the 7MM. The US had the highest number of lifetime diagnosed prevalent cases of asthma. The development of more effective therapies, particularly for severe persistent and difficult-to-treat patients, would improve quality of life and reduce the frequency with which patients experience symptoms.

Scope

• The Asthma Epidemiology Report provides an overview of the risk factors and global trends of asthma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• This report also includes a 10-year epidemiological forecast for the following segmentations in all across the 7MM: lifetime diagnosed prevalent cases of asthma; lifetime diagnosed prevalent cases of pancreatic cancer by severity.
• The asthma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Asthma Epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global asthma market.
• Quantify patient populations in the global asthma market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for asthma therapeutics in each of the markets covered.
• Understand magnitude of asthma population by severity.